fashion -WSS

fashion

author：focus 2025-10-03 00:38:59 - browse：86374

Silhouette of a medical staff, followed by another, running pushing a nursing bed. Two people talk next to the hurrying staff in the corridor — coverage from STAT — Adobe

There’s ample evidence that private equity buyouts in health care drive up costs. A new study shows quality declines, too.

Hospitals acquired by private equity saw a 25% uptick in adverse events compared with controls, according to a new study released today in the Journal of the American Medical Association. The findings add to an accumulating body of literature underscoring the harm that occurs when financial investors take over health care providers — not only hospitals, but nursing homes, hospice care, and physician practices.

Even after adjusting their findings to be more conservative, the researchers on the JAMA study found that all of the hospital-acquired conditions they studied increased three years after a private equity acquisition compared to control hospitals. Not all of the increases were statistically significant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Gain of function research would be limited under House proposal

WSS

What Henrietta Lacks's story taught me about my role as a doctor

Morphosys mixed study results for blood cancer drug

U.K. considers world's first use of meningitis vaccine to address gonorrhea

The response to Covid

My chronic pain journey would have been easier knowing 5 things % STAT

PBM reforms clear House panel

hotspot

fashion

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Anthos stroke drug appears safer than common blood thinner

What does generative AI mean for health care? We asked experts

Severe heat forecast: Where scorching temperatures will persist over the next week

Drug repurposing or repositioning? The language matters

World's first CRISPR

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Anthos stroke drug appears safer than common blood thinner

Heart attack and stroke risk calculators need revising

Men with early prostate cancer can safely opt out of treatment

entertainment

Inside the culture of fear in the White House science office of Eric Lander

4 missing after record

How to protect coverage of PrEP

World's first CRISPR

FDA's Woodcock to retire early next year

PBM reforms clear House panel

knowledge

focus

explore

knowledge